OC
EBS icon

Oakworth Capital’s Emergent Biosolutions EBS Stock Holding History

Oakworth Capital’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-446
Closed -$28K – 572
2021
Q2 		$28K Hold
446
– – ﹤0.01% 377
2021
Q1 		$41K Buy
+446
New +$45.7K ﹤0.01% 328

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Oakworth Capital's EBS Position: Q3 2021 in Review

Oakworth Capital sold out of Emergent Biosolutions (EBS) in Q3 2021, closing a stake of 446 shares — an estimated $28K sold.

Oakworth Capital first reported a position in EBS in Q1 2021 and held it in 2 quarters. The position peaked at $41K in Q1 2021. 277 funds tracked by Wall St. Rank hold EBS as of Q3 2021.

  • Oakworth Capital reported no remaining Emergent Biosolutions position as of Q3 2021 after selling out during the quarter.
  • Oakworth Capital sold 446 Emergent Biosolutions shares in Q3 2021, an estimated $28K.
  • Oakworth Capital first reported a position in Emergent Biosolutions in Q1 2021 and held it in 2 quarters.
  • Oakworth Capital's Emergent Biosolutions position peaked at $41K in Q1 2021.
  • 277 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2021.

Based on Oakworth Capital's 13F filing for Q3 2021, filed 10 Nov 2021.